Bespoke Extracts (BSPK) Asset Writedowns and Impairment (2017 - 2022)

Bespoke Extracts (BSPK) reported Asset Writedowns and Impairment of -$31825.0 for Q4 2022, down 2650.08% sequentially from $1248.0 in Q1 2017.

Bespoke Extracts (BSPK) Asset Writedowns and Impairment (2017 - 2022) Analysis & Trends

Bespoke Extracts (BSPK) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$31825.0 in Q4 2022.

For the quarter ending Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to -$31825.0; the trailing twelve-month figure through Dec 2023 stood at -$31825.0 (down 4.08% YoY), and the FY2023 full-year result was $40393.0, up 169.29% from the prior year.
Asset Writedowns and Impairment slipped to -$31825.0 in Q4 2022, from $1248.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of -$31825.0 in Q4 2022 to a low of -$31825.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Bespoke Extracts	1.12 Mn	1.11 Mn	234,175.00

Download Data